Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer
Anaplastic lymphoma kinase (ALK) gene rearrangements have been identified in lung cancer at 3–7% frequency, thus representing an important subset of genetic lesions that drive oncogenesis in this disease. Despite the availability of multiple FDA-approved small molecule inhibitors targeting ALK fusio...
Main Authors: | Wei Wu, Franziska Haderk, Trever G. Bivona |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-11-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/9/12/164 |
Similar Items
-
Anaplastic Lymphoma Kinase (ALK) in Posterior Cranial Fossa Tumors: A Scoping Review of Diagnostic, Prognostic, and Therapeutic Perspectives
by: Danai-Priskila V. Mousa, et al.
Published: (2024-02-01) -
A New Target in Non-small Cell Lung Cancer: EML4-ALK Fusion Gene
by: Huijuan WANG, et al.
Published: (2011-06-01) -
From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL)
by: Michael T. Werner, et al.
Published: (2017-10-01) -
Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer
by: Anna M. Wulf, et al.
Published: (2021-10-01) -
Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma
by: Huan Zhang, et al.
Published: (2021-11-01)